Dendreon (NASDAQ:DNDN) Swings to Loss in Fiscal Q4; Stock Tumbles – DNDN, MDVN, PPHM, NLNK

Dendreon Corporation (NASDAQ:DNDN) on Monday announced a quarterly loss evaluated against a profit in previous year as revenue tumbled and restructuring expenses weighed on the biotechnology corporation.

The Seattle, Washington based company net loss was $38.7 million or 26 cents a share in fiscal fourth-quarter, evaluated against a profit of $38.1 million or 26 cents a share.

The loss was 26 cents a share without special items. Thomson Reuters analysts on average forecasted a loss of 56 cents a share. Revenue for the most recent quarter tumbled to $85.5 million from $202.1 million in previous year.

Shifting reader’s focus to broader market, let us consider market performance of other stocks that significantly affect same sector. Medivation, Inc. (NASDAQ:MDVN) fell -3.88% to settle at $47.59, Peregrine Pharmaceuticals (NASDAQ:PPHM) moved down -12.03% to end at $1.39 while NewLink Genetics Corp (NASDAQ:NLNK) jumped +2.11% to finish at $12.10 on Monday.

Dendreon Corporation (NASDAQ:DNDN) last session’s volume of 12.27 million shares was higher than its average volume of 8.10 million shares. The stock after opening at $5.55 hit high price of $6.09 and then closed at $5.42 by scoring -4.41%.

DNDN generated revenue of $442.18 million in the previous twelve months and earned -$316.82 million. The Company showed a negative -71.65% in the net profit margin as well as in its operating margin which remained at -59.60%. Company’s annual sales growth for the past five years was 316.37%.

The DNDN’s past twelve months’ price to sales ratio was 1.89 and price to cash ratio remained 2.14. As far as the returns are concerned, DNDN’s return on equity was recorded as -176.03% and return on investment decreased -62.83% while its return on asset stayed at -37.48%.

The stock showed weekly downbeat performance of -10.71% which was maintained for the month at -13.97%. Likewise the positive performance for the quarter was recorded as 23.46% and for the year was -60.52% while the YTD performance remained at 2.46%.

DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with! CLICK HERE TO START YOUR FREE 30-DAY TRIAL

This entry was posted in Healthcare, Latest Headlines and tagged , , , , , , , , , , , . Bookmark the permalink.